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Abstract
It was recently recognized that some chronic myeloid leukemia patients with a complete molecular response could sustain that response after discontinuation of imatinib. To characterize the clinical outcomes and profiles of chronic phase chronic myeloid leukemia patients who could discontinue imatinib, we conducted a nationwide survey in Japan. Among 3,242 imatinib-treated chronic myeloid leukemia patients, 50 were identified who discontinued imatinib for at least 6 months; of those, 43 were analyzed. Molecular recurrence was detected in 19 patients, and a complete molecular response rate was estimated to be 47% following imatinib discontinuation. Based on multivariate regression analysis, imatinib dose intensity and prior interferon-a administration were independently predictive of molecular recurrence within 12 months. The depth of the molecular response should be a factor influencing long-term sustained complete molecular response after discontinuation of imatinib. Additionally, an immunological
Introduction
Imatinib treatment dramatically improves survival in chronic myeloid leukemia (CML) patients, which has made imatinib the standard-of-care for chronic phase CML. But whether the effects of imatinib can be considered a cure remains controversial. This may be because primitive, quiescent, Philadelphia-positive stem cells from patients with CML are insensitive to imatinib in vitro 1 , and residual BCR/ABL+ hematopoietic progenitors are present in patients who achieve a complete cytogenetic response (CCyR) with imatinib 2 .
Recently, it was recognized that some patients with a complete molecular response (CMR) are able to sustain this response after discontinuation of imatinib 3 . In a non-randomized prospective study, Mahon et al. reported that among patients with a CMR lasting at least 2 years, the CMR was sustained in 41% after discontinuation of imatinib. However, this strategy requires further validation and much longer follow-up. At present, there appear to be no patients or disease characteristics that identify in advance those who can safely discontinue imatinib. Consequently, cure has not yet been proven, and life-long therapy with imatinib is still the consensus recommendation 4 .
Discontinuing imatinib in CML should only be considered in a clinical trial with strict molecular monitoring 3, 5 .
Nevertheless, the literature contains several case reports of CML patients in whom imatinib had to be discontinued for various reasons [6] [7] [8] [9] [10] [11] [12] [13] . Some of those patients relapsed molecularly, but others did not. This finding raises the question, How deep does the molecular response to imatinib treatment need to be and how long must imatinib treatment be continued after achieving CMR before the drug can be safely discontinued? There has been no regional retrospective survey of the clinical outcomes of CML patients after discontinuation of imatinib.
To characterize the clinical outcomes and profiles of CML patients who have been off imatinib therapy for at least 6 months, we conducted a nationwide survey of CML patients in Japan and report our findings here.
Design and Methods
Data collection
We first sent questionnaires to 780 hematologists in the Japanese Society 
Molecular response
In general practice, the molecular response was assessed at least every 
Statistical analysis
Statistical analyses were carried out using SPSS statistical software (SPSS Japan Inc., Tokyo, Japan, version 17.0). Non-parametric values or numbers were compared between two groups using the Mann-Whitney test, the 7 χ2 test or Fisher's exact test. Time to molecular relapse was measured from the date of imatinib discontinuation to the date of molecular recurrence, or the date of last molecular examination for patients who did not relapse.
Relapse-free survival was estimated using the Kaplan-Meier method. Survival rate was compared between two groups using the log-rank test. Stepwise forward selection multiple logistic analysis for molecular recurrence by 12 months was performed to determine the effect of the variables examined in a univariate analysis. P-values of less than 0.05 were considered significant.
Results and Discussion
This is the first survey of outcomes after imatinib discontinuation in Japan. The survey is estimated to cover about one-third of Japanese CML patients. One question we asked was, how many patients are able to sustain CMR after imatinib discontinuation. Only 50 patients (1.5%) who had discontinued imatinib therapy for at least 6 months were identified, and 43 patients were analyzed in this retrospective study. The median age at diagnosis of CML was 57 years (range 18-80). The male/female ratio was 19:24. All patients were in the chronic phase, with no history of progression to the accelerated phase or blast crisis (AP/BC), and all had achieved CMR before imatinib discontinuation. Based on their Sokal scores, 25 patients were classified as low risk, 15 patients as intermediate risk, and 3 patients as high risk.
The reasons imatinib was discontinued were adverse events (18 patients), patient's request due to cost (14 patients), patient's desire to become pregnant (3 patients), and long undetectable residual disease (8 patients). In this study, the male/female ratio was reverse that commonly observed. This might indicate that women are more likely than men to want to stop imatinib because of some adverse event (e.g., facial edema, skin rash), and could also reflect the desire to become pregnant.
Seventy-two percent of patients were treated with the standard dose or a higher dose of imatinib (<400 mg, 12 patients; 400 mg, 22 patients; >400 mg, 9
patients; median daily dose, 400 mg; range, 100-700 mg). and all patients remain alive. The relapse-free survival (RFS) rate at 5 years was estimated to be 47%, while median RFS was determined to be 41 months using the Kaplan-Meier method. Twenty-four patients among the 43 (56%)
analyzed further showed sustained CMR without a molecular recurrence after discontinuation. Although the sample size was small, it seems clear that imatinib treatment could be stopped in some patients.
We also asked, what is the profile of patients who can sustain CMR without a molecular recurrence after discontinuation of imatinib, and how long after achieving CMR should imatinib treatment be continued before attempting cessation? Comparison of patients who did and did not show molecular recurrence within 12 months after stopping imatinib therapy revealed several significant differences (Table 1) . First, the median duration of imatinib therapy before cessation was 51.7 months in patients without molecular recurrence, which is significantly (p=0.0228) longer than the 26.3 months of therapy received by patients with molecular recurrence. Second, the estimated dose of imatinib before cessation was 576.8 g in patients without molecular recurrence, which is significantly (p=0.0042) greater than the 275.4 g in patients with molecular recurrence. Third, IFN-a was administered prior to cessation significantly (p=0.0102) more frequently in patients without molecular recurrence within 12 months. On the other hand, no significant differences were found with respect to age, sex, Sokal risk, imatinib daily dose, combination with IFN-a, or time to CMR. In the STIM study, the probability of a sustained CMR at 12 months differed between Sokal risk groups (p=0.008) 3 . In our study, a molecular 10 recurrence by 12 months occurred in only one of three patients in the high-risk group, 7 of 13 patients in the intermediate-risk group, and 6 of 24 patients in the low-risk group. Because of the sample size in this study, we were unable to not detect an effect of Sokal score (p=0.2135).
Importantly, the median duration of CMR before cessation was 32.5 months in patients without molecular recurrence, which was significantly (p=0.0025) longer than the 6.0 months in patients with molecular recurrence.
Moreover, there was a significant difference in the estimated RFS rates following discontinuation between patients in whom CMR was sustained for more than 24 months prior to imatinib discontinuation and those sustaining a CMR for less than 24 months (78% vs. 15%, p=0.0002 by Log-rank test, Figure 1 ). The duration of CMR was one of the eligibility criteria for the STIM trial 3 . Because patients who relapsed and restarted imatinib within 6 months after its discontinuation were not included in this study, as dictated by the inclusion criteria, we are able to show that the estimated RFS rates at 5 years were much higher (78%) among patients who sustained a CMR for >24 months before cessation of therapy in this series than in the STIM study. However, in a multivariate regression analysis, only imatinib dose intensity and prior IFN-a administration were independently predictive of a molecular recurrence within 12 months ( Table 2 Although it is still a small subset of CML patients, our data also suggest that imatinib could achieve a clinical "cure".
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